Basilea Pharmaceutica Stock
Basilea Pharmaceutica AG
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- CEO
- David Veitch
- Employees
- 200
- Market cap
- CHF813 M
- IPO
- 25/03/2004
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise that focuses on inventing and advancing treatments to address critical unmet medical needs. The company concentrates its efforts primarily within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Basilea Pharmaceutica stock: price history
1D
-4.4%
1W
+0.2%
1M
-1.4%
6M
+16.9%
YTD
+19.9%
1Y
+34.2%
2Y
+45.9%
5Y
+52.3%
10Y
-9.3%
Next earnings date
Next earnings date
16/02/2027 (in 122 days)
Volatility around earnings
~18% stronger price swings than usual
Basilea Pharmaceutica stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in the development of therapies to address unmet medical needs in oncology and infectious diseases. The product portfolio includes the antifungal Cresemba and the antibiotic Zevtera, which are either already approved in the EU or US or in advanced clinical development. Additionally, the company maintains a pipeline of drug candidates such as Derazantinib and Lisavanbulin being developed for various cancer indications.
- Revenue model
- Hardware sales
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Basilea Pharmaceutica
Basilea Pharmaceutica stock metrics
P/E
15.4
P/B
5
EV/EBITDA
11.32
RETURN ON EQUITY
17.2%
NET MARGIN
23.5%
DEBT/EQUITY
0.51
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.1%
FLOAT SHARES
11,410,018
AVG. DAILY VOLUME (30D)
32,043
Dividends
Comparable stocks
Frequently asked questions about Basilea Pharmaceutica stock
What does Basilea Pharmaceutica do?
Basilea Pharmaceutica AG is a company in the Healthcare sector, Biotechnology industry, headquartered in Switzerland.
The CEO is David Veitch, the company employs around 200 people.
The IPO was on 25/03/2004; the stock trades on SIX under the ticker BSLN.SW.
When does Basilea Pharmaceutica report next?
The next earnings date is 16/02/2027.
Around past earnings, price swings were roughly 18% stronger than usual.
Does Basilea Pharmaceutica pay a dividend?
Yes. The last dividend was CHF 5.00 per share, ex-date 11/04/2013, paid on 21/06/2013.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Basilea Pharmaceutica?
Comparable stocks include BeOne Medicines, Pharvaris, Idorsia, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx and Revolution Medicines.
How can I get Basilea Pharmaceutica stock analyzed?
Clicking "Analyze stock" lets five strategies assess Basilea Pharmaceutica against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.